Applied Therapeutics Inc (NASDAQ: APLT) has seen a rise in its stock price by 5.25 in relation to its previous close of 0.62. However, the company has experienced a -3.84% decline in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-19 that RADNOR, PA / ACCESS Newswire / January 19, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Applied Therapeutics, Inc. (“Applied Therapeutics”) (NASDAQ:APLT) on behalf of those who purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024, and December 2, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 18, 2025.
Is It Worth Investing in Applied Therapeutics Inc (NASDAQ: APLT) Right Now?
The stock has a 36-month beta value of 1.92. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for APLT is 86.61M, and at present, short sellers hold a 22.12% of that float. On January 20, 2025, the average trading volume of APLT was 6.44M shares.
APLT’s Market Performance
APLT’s stock has seen a -3.84% decrease for the week, with a -43.22% drop in the past month and a -92.58% fall in the past quarter. The volatility ratio for the week is 13.97%, and the volatility levels for the past 30 days are at 13.07% for Applied Therapeutics Inc The simple moving average for the past 20 days is -19.86% for APLT’s stock, with a -87.82% simple moving average for the past 200 days.
Analysts’ Opinion of APLT
UBS, on the other hand, stated in their research note that they expect to see APLT reach a price target of $2, previously predicting the price at $13. The rating they have provided for APLT stocks is “Neutral” according to the report published on December 02nd, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to APLT, setting the target price at $4 in the report published on November 29th of the previous year.
APLT Trading at -83.18% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.85% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 13.97%, as shares sank -40.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -92.95% lower at present.
During the last 5 trading sessions, APLT fell by -3.84%, which changed the moving average for the period of 200-days by -89.75% in comparison to the 20-day moving average, which settled at $0.8148. In addition, Applied Therapeutics Inc saw -23.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Funtleyder Leslie D., who sale 13,530 shares at the price of $5.83 back on Aug 22 ’24. After this action, Funtleyder Leslie D. now owns 277,911 shares of Applied Therapeutics Inc, valued at $78,880 using the latest closing price.
Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 22,681 shares at $5.83 during a trade that took place back on Aug 22 ’24, which means that Perfetti Riccardo is holding 986,853 shares at $132,230 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- 437.36 for the present operating margin
- 3.79 for the gross margin
The net margin for Applied Therapeutics Inc stands at 887.73. The total capital return value is set at -12.14.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -41.52. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -127.99.
Currently, EBITDA for the company is -64.53 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 99.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
To sum up, Applied Therapeutics Inc (APLT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
